Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults

• Status: Enrolling by invitation
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The study employs tau positron emission tomography (PET) imaging in a well-characterized multi-racial/ethnic cohort to examine the extent to which tau pathology is associated with cognition, differences in tau pathology across racial/ethnic groups, and the relationship between MRI markers of small-vessel cerebrovascular disease and tau pathology. The study also investigates amyloid-dependent tau spreading.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Adam Brickman
• Collaborator: National Institute on Aging (NIA)

Criteria

Inclusion Criteria:

• Aged 35 - 85 years

• Have either mild cognitive impairment or mild clinical Alzheimer's disease; or have no problem with memory or thinking.

• Able to participate in all scheduled evaluations and to complete all required tests and procedures

• Considered likely to comply with the study protocol and to have a high probability of completing the study

Exclusion Criteria:

• Past or present history of a certain brain disease other than mild cognitive impairment or mild clinical Alzheimer's disease.

• Certain significant medical conditions. Examples are uncontrolled epilepsy or multiple serious injuries.

• Unable to lie still for PET scans.

• Radiation exposure for research studies in the last year that would put you past allowable limits if included in this study.

• Participation in the last year in a clinical trial for a disease modifying drug for AD unless it can be determined that your received placebo and not active drug.

• Conditions that preclude entry into the scanner (e.g. claustrophobia, etc.).

• Inability to have a catheter in your vein for the injection of the radioligand (dye).

• Currently pregnant or breastfeeding.